Adarx is a technology company that specializes in developing advanced data analytics and artificial intelligence solutions for healthcare and life sciences. Their platform aims to accelerate drug discovery and development by providing insights through data integration, machine learning, and predictive modeling.

Adarx

AvengeBio was a biotechnology company that is now permanently closed.

AvengeBio

ADARx Pharmaceuticals, Inc., located in San Diego, is a clinical stage biotechnology company committed to turning cutting-edge science into life-saving therapeutics.  ADARx has developed proprietary RNA targeting platforms and oligonucleotide delivery technologies for inhibition, degradation, and editing disease-causing mRNA.  ADARx has a growing pipeline of RNA targeting therapeutics for treating diseases across a range of therapeutic areas including genetic, cardiometabolic, complement-mediated diseases and central nervous system diseases.  We are well-financed by a syndicate of renowned VC firms. 

ADARx currently has multiple active programs in development. Our lead candidate is at the clinical stage.  

Lilly Asia Ventures

OrbiMed

Sirona Capital

SR One

Ascenta Capital

Vivo Capital

BlackRock

Bain Capital Life Sciences

Cormorant Asset Management

Redmile Group

Marshall Wace

HBM Healthcare Investments AG

T. Rowe Price

Venrock Healthcare Capital Partners

ADARx Pharmaceuticals Inc.

Metric
Company Name	Adarx	AvengeBio
Symbol
MSH ID	COM:ADARX	COM:AVENGEBIO
Market	PRIVATE	PRIVATE
Sector	Technology	Healthcare & Health Services
Industry	Healthcare Technology	Biotechnology
Country	US	US
Stage
Employee Count	53	11
Website	adarx.com	avengebio.com
LinkedIn	adarx-pharmaceuticals-inc
Founders

Metric
Market Cap	1.20B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score	1.27
28-Day Growth Score	53.28
90-Day Growth Score	53.80
365-Day Growth Score	2.30

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:ADARX

Adarx

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue